Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07667829

Vasopressor Agents in Pulmonary Hypertension Crisis

Comparison of the efficacy and safety of three vasoactive agents-dopamine, norepinephrine, and epinephrine-in the treatment of patients with pulmonary hypertension crisis: prospective, randomised controlled trial monitored by haemodynamic monitoring

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Pulmonary Arterial Hypertension (PAH) Cardiovascular Diseases Chronic Thromboembolic Pulmonary Hypertension (CTEPH) Heart Diseases Heart Failure Hypertension Hypertension, Pulmonary Lung Diseases Pulmonary Arterial Hypertension Respiratory Tract Diseases Vascular Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Chinese Academy of Medical Sciences, Fuwai Hospital, Beijing, Beijing Municipality, China

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age > 18 years old;
  • Signed informed consent form;
  • Confirmed diagnosis of arterial pulmonary hypertension (PAH) and/or chronic thromboembolic pulmonary hypertension (CTEPH);
  • Presenting with manifestations of pulmonary hypertensive crisis;
  • Receiving both diagnosis and treatment in-hospital;
  • No intravenous administration of the vasopressor drugs (including dopamine, norepinephrine, and epinephrine) under study at enrollment.

Exclusion criteria

  • At SCAI stage D or stage E ;
  • Patients who only receive a diagnosis but no treatment in the hospital;
  • Uncontrolled hyperthyroidism;
  • Complicated with angle-closure glaucoma;
  • Hypersensitivity to the study drug;
  • Ongoing use of halogenated hydrocarbon general anesthetics such as cyclopropane and halothane;
  • Ongoing use of monoamine oxidase inhibitor (MAOI) antidepressants or anti-Parkinson drugs (phenelzine, tranylcypromine, isocarboxazid, moclobemide);
  • Pregnancy;
  • Already receiving the vasopressor drugs (dopamine, norepinephrine, epinephrine) under study at enrollment.

Treatment and study plan

norepinephrine

Drug

The initial dose is 0.02 mg/kg/min of norepinephrine; each dose adjustment (increase or decrease) is 0.02 mg/kg/min of norepinephrine; the maximum dose of norepinephrine is 0.2 mg/kg/min.

Dopamine

Drug

The initial dose is 2 μg/kg/min of dopamine; each dose adjustment (increase or decrease) is 2 μg/kg/min of dopamine; the maximum dose of dopamine is 20 μg/kg/min

Epinephrine

Drug

The initial dose is 0.02 μg/kg/min of epinephrine; each adjustment (up or down) is 0.02 μg/kg/min of epinephrine; the maximum dose of epinephrine is 0.2 μg/kg/min

Primary outcomes

  1. All-cause mortality within 28 days

    Time frame: 28 days after enrolment

Secondary outcomes

  1. Haemodynamic parameters

    Time frame: Haemodynamic parameters at H0, H6, H24, H48 and H72

  2. Severe arrhythmia (ventricular tachycardia, ventricular fibrillation)

    Time frame: Time of onset of severe arrhythmia

  3. Adverse effects of vasopressors

    Time frame: Time at which adverse effects occur

  4. Arterial Blood Gas Analysis

    Time frame: H0, H6, H24, H48, H72, Day 7, Day 14, Day 21, Day 28 (if the length of hospital stay is between 7 and 28 days, a test must be performed on the day of discharge)

  5. Vital Signs

    Time frame: Record at H0, H2, H4, H6, H12, H24, H48 and H72 after administration of medication; thereafter, record once every 24 hours until the day of discharge

  6. BNP or NT-proBNP

    Time frame: H0, H24, H48, H72, Day 7, Day 14, Day 21, Day 28 (if the length of hospital stay is between 7 and 28 days, a test must be performed on the day of discharge)

  7. Echocardiographic parameters

    Time frame: H0, H24, H48, H72, Day 7, Day 14, Day 21, Day 28 (if the length of hospital stay is between 7 and 28 days, a measurement must be taken on the day of discharge)

Study contacts

Contact information is provided by the study sponsor or research team.

Qing Gu,MD

CONTACT

[email protected]

+86 010-88392814

Sponsors and collaborators

Lead sponsor

China National Center for Cardiovascular Diseases

Other Gov

Registry information

Official study title

Comparison of the Efficacy and Safety of Dopamine, Norepinephrine and Epinephrine in the Treatment of Pulmonary Hypertensive Crisis Under Hemodynamic Monitoring

Important dates

Study start
2026
Primary completion
2028
Study completion
2029
First posted
Jun 25, 2026
Registry last updated
Jun 25, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.